Protective effects of a by-product of the pecan nut industry (Carya illinoensis) on the toxicity induced by cyclophosphamide in rats Carya illinoensis protects against cyclophosphamide- induced toxicity

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 29, Issue 3, 2010, Pages 185-197

  Benvegnu D M ^a   Barcelos, R C S ^a   Boufleur, N ^a   Reckziegel, P ^a   Pase, C S ^a   Muller L G ^a   Martins, N M B ^a   Vareli, C ^a   Burger M E ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Antioxidant; Carya illinoensis; Cyclophosphamide; Oxidative stress; Pecan nut shells

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; CARYA ILLINOENSIS EXTRACT; CATALASE; CYCLOPHOSPHAMIDE; GLUTATHIONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; WATER; PLANT EXTRACT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLADDER; BLEEDING; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; EDEMA; ENZYME ACTIVITY; ERYTHROCYTE; HEART; HISTOLOGY; KIDNEY; LAMINA PROPRIA; LEUKOCYTE; LIPID PEROXIDATION; LIVER; MALE; NONHUMAN; OXIDATIVE STRESS; PECAN; PLASMA; PRIORITY JOURNAL; RAT; VITAMIN BLOOD LEVEL; ANIMAL; BLOOD; METABOLISM; PHYTOTHERAPY; WISTAR RAT;

CARYA ILLINOINENSIS; RATTUS;

ANIMALS; ASCORBIC ACID; CARYA; CATALASE; CYCLOPHOSPHAMIDE; GLUTATHIONE; LIPID PEROXIDATION; MALE; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, WISTAR;

EID: 79953008532     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v29.i3.30     Document Type: Article

References (57)

1. Hancock BG. Development of pecan industry. In: Hancock BG, editor. Texas Pecan Handbook. Texas Agricultural Extension Service; 1997. p.1-7.
2. Rajaram S, Burke K, Connell B, Myint T, Sabate J. A monounsaturated fatty acid-rich pecan-enriched diet favorably alters the serum lipid profile of healthy men and women. J. Nutr. 2001;131:2275-2279.
3. Worley RE. 1994. Pecan physiology and composition. In: Santerre, C.R. editor. Pecan Technology. New York: Chapman & Hall; 1994. p. 39-45.
4. Villarreal-Lozoya JE, Lombardini L, Cisneros-Zevallos L. Phytochemical constituents and antioxidant capacity of different pecan [Carya illinoinensis (Wangenh.) K. Koch] cultivars. Food Chem. 2007;102:1241-1249.
5. Pecantea [homepage on the Internet]. Brasil: Pecantea - Chá de Casca de Noz-pecã [updated 2009 November 19]. Available from: http://www.pecantea.com.br/index2.html.
6. Velioglu YS, Mazza G, Gao L, Oomah BD. Antioxidant activity and total phenolics in selected fruits, vegetables, and grain products. J Agric Food Chem. 1998;46:4113-4117.
7. Zincke H, Woods JE. Donor pretreatment in cadaver renal transplantation. Surg Gynecol Obstet. 1977;145:183-188.
8. Kern JC, Kehrer JP. Acrolein-induced cell death: a caspase influenced decision between apoptosis and oncosis/necrosis. Chem Biol Interact. 2002;139:79-95.
9. Sladek N. Metabolism of cyclophosphamide by rat hepatic microsomes. Cancer Res. 1971;1:901-908.
10. Bukowski R. The need for cytoprotection. Eur J Cancer. 1999;32A:S2-S4.
11. Fraiser LH, Kanekel S, Kehrer JP. Cyclophosphamide toxicity: characterizing and avoiding the problem. Drugs. 1991;42:781-795.
12. Shanholtz C. Acute life-threatening toxicity of cancer treatment. Crit Care Clin. 2001;17:483-502.
13. Snover DC, Weisdorf S, Bloomer J, McGlave P, Weisdorf D. Nodular regenerative hyperplasia of the liver following bone marrow transplantation. Hepatology. 1989;9:443-448.
14. Shulman HM, McDonald GB, Matthews D. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology. 1980;79:1178-1191.
15. Rossi R. Nephrotoxicity of ifosfamide - moving towards understanding the molecular mechanisms. Nephrol Dial Transplant. 1997;12:1091-1092.
16. Abraham P, Sugumar E. Increased glutathione levels and activity of phenyl acetate esterase (PON1) in the liver of rats after a single dose of cyclophosphamide: A defense mechanism? Exp Toxicol Pathol. 2008;59:301-306.
17. Appelbaum FR, Strauchen JA, Graw Jr RG, Savage DD, Kent KM, Ferrans VJ, Herzig GP. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet. 1976;1:58-62.
18. Levine LA, Ritchie JP. Urological complications of cyclophosphamide. J Urol. 1989;141:1063-1069.
19. Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol. 2007;23:303-312.
20. Kalyanaraman B, Nemec J, Sinha BK. Characterization of free-radicals produced during oxidation of etoposide (vp-16) and its catechol and quinone derivatives - an esr study. Biochemistry. 1989;28:4839-4846.
21. Haque R, Bin-Hafeez B, Parvez S, Pandey S, Sayeed I, Ali M, Raisuddin S. Aqueous extract of walnut (Juglans regia L.) protects mice against cyclophosphamide- induced biochemical toxicity. Hum Exp Toxicol. 2003;22:473-480.
22. Dorr RT, Lagel K. Effect of sulfhydryl compounds and glutathione depletion on rat-heart myocyte toxicity induced by 4-hydroperoxycyclophosphamide and acrolein in-vitro. Chem Biol Interact. 1994;93:117-128.
23. Patel JM. Stimulation of cyclophosphamide-induced pulmonary microsomal lipid-peroxidation by oxygen. Toxicology. 1987;45:79-91.
24. Patel JM, Block ER. Cyclophosphamide-induced depression of the antioxidant defense-mechanisms of the lung. Exp Lung Res. 1985;8:153-165.
25. Manda KL, Bhatia AL. Prophylactic action of melatonin against cyclophosphamide-induced oxidative stress in mice. Cell Biol Toxicol. 2003;19:367-72.
26. Singh DK, Lippman SM. Cancer chemoprevention part 1: retinoids and carotenoids and other classic antioxidants. Oncology. 1998;12:1643-1660.
27. Sudharsan PT, Mythili Y, Selvakumar E, Varalakshmi P. Lupeol and its ester ameliorate the cyclophosphamide provoked cardiac lysosomal damage studied in rat. Mol Cell Biochem. 2006;282:39-44.
28. Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic Biol Med. 2001;31:331-335.
29. Jacques-Silva MC, Nogueira CW, Broch LC, Flores EM, Rocha JB. Diphenyl diselenide and ascorbic acid changes deposition of selenium and ascorbic acid in liver and brain of mice. Toxicol Appl Pharmacol. 2001;88:119-125.
30. Ohkawa H, Ohishi H, Yagi K. Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358.
31. Boyne AF, Ellman GL. A methodology for analysis of tissue sulfhydryl components, Anal Biochem. 1972;46:639-653.
32. Galley H, Davies MJ, Webster NR. Ascorbil radical formation in patients with sepsis: effects of ascorbate loading. Free Radic Biol Med. 1996;20:139-143.
33. Aebi H. Catalase in vitro. Meth Enzymol. 1984;105:121-126.
34. Lee LK, Harman GS, Hohl RJ, Gingrieh RD. Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment. Bone Marrow Transplant. 1996;18:573-577.
35. Prado ACP, Aragão AM, Fett R, Block JM. Antioxidant properties of Pecan nut [Carya illinoinensis (Wangenh.) C. Koch] Shell infusion. Grasas Aceites. 2009;60:330-335.
36. Lu Z, Nie G, Belton PS, Tang H, Zhao B. Structure- activity relationship analysis of antioxidant ability and neuroprotective effect of gallic acid derivatives. Neurochem Int. 2006;48:263-274.
37. Mythili Y, Sudharsan PT, Selvakumar E, Varalakshmi P. Protective effect of dl-a-lipoic acid on cyclophosphamide induced oxidative cardiac injury. Chem Biol Interact. 2004;151:13-19.
38. Senthilkumar S, Devaki T, Manohar BM, Babu MS. Effect of squalene on cyclophosphamide-induced toxicity. Clin Chim Acta. 2006;364:335-342.
39. Olson RD, Boerth RC, Gerber JG, Nies AS. Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci. 1981;29:1393-1401.
40. Takacs IE, Matkovics B, Varga SI, Homolay P, Feer G, Seres T. Study of the myocardial antioxidant defense in various species. Pharmacol Res. 1992;25:177-178.
41. Ren S, Slatterly JT. Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine. AAPS Pharm Sci. 1999;1:E14.
42. Atkinson K, Biggs J, Ashby M, Concannon A, Dodds A. Preparative regimens for marrow transplantation containing busulfan are associated with hemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis. Bone Marrow Transplant. 1987;2:385-394.
43. Bhattacharya A, Lawrence RA, Krishnan A, Zaman K, Sun D, Fernande G. Effect of dietary n-3 and n-6 oils with and without food restriction on activity of antioxidant enzymes and lipid peroxidation in livers of cyclophosphamide treated autoimmune-prone nzb/w female mice. J Am Coll Nutr. 2003;22:388-399.
44. Premkumara K, Pachiappana A, Abrahamb SK, Santhiyaa ST, Gopinatha PM, Ramesh A. Effect of Spirulina fusiformis on cyclophosphamide and mitomycin- C induced genotoxicity and oxidative stress in mice. Fitoterapia. 2001;72:906-911.
45. Kopecna L. Late effects of anticancer therapy on kidney function in children with acute lymphoblastic leukemia. Bratisl Lek Listy. 2001;102:357-360.
46. Horvath JJ, Witmer CM, Witz G. Nephrotoxicity of the 1:1 acrolein-glutathione adduct in the rat. Toxicol Appl Pharmacol. 1992;117:200-207.
47. Sugumar E, Abraham P. Normal plasma creatinine level despite histological evidence of damage and increased oxidative stress in the kidneys of cyclophosphamide treated rats. Clin Chimi Acta. 2007;376:244-245.
48. Ascensao A, Ferreira R, Marques F, Oliveira E, Azevedo V, Soares J, Magalhães J. Effect of offroad competitive motocross race on plasma oxidative stress and damage markers. Br J Sports Med. 2007;41(2):101-105.
49. Lee IM. Antioxidant vitamins in the prevention of cancer. Proc Assoc Am Phys. 1999;111:10-15.
50. Manoharan S, Kolanjiappan K, Kayalvizhi M. Enhanced lipid peroxidation and impaired enzymic antioxidant activities in the erythrocytes of patients with cervical carcinoma. Cell Mol Biol Lett. 2004;9:699-707.
51. Bischel MD. Cyclophosphamide-hemorrhagic cystitis following prolonged low-dose therapy. JAMA. 1979;242:238-239.
52. Datta K, Chin A, Ahmed T, Qing WG, Powell KL, Simhambhatla P, MacLeod MC, Stoica G, Kehrer JP. Mixed effects of 2,6-dithiopurine against cyclophosphamide mediated bladder and lung toxicity in mice. Toxicology. 1998;125:1-11.
53. Cavalletti E, Tofanetti O, Zunino F. Comparison of reduced glutathione with 2-mercaptoethane sulfonate to prevent cyclophosphamide-induced urotoxicity. Cancer Lett. 1986;32:1-6.
54. Jaakkola K, Lahteenmaki P, Laakso J, Harju E, Tykka H, Mahlberg K. Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer Res. 1992;12:599-606.
55. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004;3:294-300.
56. Klimberg VS. Glutamine, cancer and its therapy. Am J Surg. 1996;172:418-424.
57. Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol. 2003;41:1447-1452.